A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases

Drugs in R and D

Volumn 9, Issue 3, 2008, Pages 137-145

  Gupta, Kaveri ^a   Cooper, Curtis ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

CpG containing oligodeoxynucleotides, therapeutic use; Hepatitis B; Infections; Influenza virus infections; Research and development; Toll like receptor 9 agonists, therapeutic use; Vaccines, therapeutic use

Indexed keywords

1018 ISS; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS B VACCINE; INFLUENZA VACCINE; PEGINTERFERON; RECOMBINANT HEPATITIS B VACCINE; RIBAVIRIN; TOLL LIKE RECEPTOR 9;

ANTIBODY TITER; CLINICAL TRIAL; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION; INFLUENZA; INJECTION SITE PAIN; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA, HUMAN; MALARIA; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; VACCINES;

EID: 43249097514     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200809030-00001     Document Type: Review

References (49)

1. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9
2. Mitcham JL, Parnet P, Bonnert TP, et al. T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family. J Biol Chem 1996; 271: 5777-83
3. Medzhitov R, Preston-Hurlburt P, Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7
4. Chaudhary PM, Ferguson C, Nguyen V, et al. Cloning and characterization of two Toll/interleukin-1 receptor-like genes TIL3 and TIL4: evidence for a multi-gene receptor family in humans. Blood 1998; 91: 4020-7
5. Rock FL, Hardiman G, Timans JC, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 1998; 95: 588-93
6. Kindt TJ, Osborne BA, Goldsby RA. Kuby immunology. 6th ed. New York: WH Freeman and Company Publishing, 2007
7. Kawai T, Akira S. Toll-like receptor downstream signaling. Arthritis Res Ther 2005; 7: 12-9
8. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001; 98: 9237-42
9. Sandor F, Buc M. Toll-like receptors: I. Structure, function and their ligands. Folia Biol (Praha) 2005; 51: 148-57
10. Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000; 68: 455-63
11. Demi L, Schirmbeck R, Reimann J, et al. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin Chem Lab Med 1999; 37: 199-204
12. Weeratna RD, Brazolot Millan CL, McCluskie MJ, et al. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 2001; 32: 65-71
13. Zhou X, Zheng L, Liu L, et al. T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides. Scand J Immunol 2003; 58: 350-7
14. Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-76
15. Kinjo T, Miyagi K, Nakamura K, et al. Adjuvant effect of CpGHCV oligodeoxynucleotide in anti-fungal chemotherapy against fatal infection with Cryptococcus neoformans in mice. Microbiol Immunol 2007; 51: 741-6
16. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007; 4: 289-94
17. Mutwiri G, Pontarollo R, Babiuk S, et al. Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol 2003; 91: 89-103
18. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000; 164: 1617-24
19. Jones TR, Obaldia III N, Gramzinski RA, et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 1999; 17: 3065-71
20. Verthelyi D, Gursel M, Kenney RT, et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol 2003; 170: 4717-23
21. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 2001; 3: 15-24
22. Weeratna R, Comanita L, Davis HL. CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol Cell Biol 2003; 81: 59-62
23. Davis HL, Suparto II, Weeratna RR, et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000; 18: 1920-4
24. Halperin SA, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003; 21: 2461-7
25. Halperin SA, Dobson S, McNeil S, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006; 24: 20-6
26. Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24: 693-701
27. Cooper CL, Davis HL, Angel JB, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005; 19: 1473-9
28. Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004; 22: 3136-43
29. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38: S158-68
30. Cooper C. CpG adjuvant + HBV vaccination in HIV infection achieves long-term seroprotection for as long as 5 years [abstract no. 2007P-203]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, CROI 2007; 2007, Feb 25-28; Los Angeles (CA)
31. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-29
32. McHutchison JG, Bacon BR, Gordon SC, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007; 46: 1341-9
33. Lawitz E, Freilich B, Gordon SC, et al. Early viral response and on treatment response to CPG 10101 (ACTILON), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response [abstract no. 96]. Presented at the Liver Meeting 2006 AASLD; 2006 Oct 27-31; Boston (MA)
34. Coley Pharmaceutical Group. Updates hepatitis C drug development strategy: Wellesley, MA, 2007 [online]. Available from URL: http://www.eatg.org/ news/newsitem.php?.id=757 [Accessed 2007 Jan 22]
35. Palache AM. Influenza vaccines: a reappraisal of their use. Drugs 1997; 54: 841-56
36. Meiklejohn G, Eickhoff TC, Graves P, et al. Antigenic drift and efficacy of influenza virus vaccines, 1976-1977. J Infect Dis 1978; 138: 618-24
37. Ruben FL. Prevention and control of influenza: role of vaccine. Am J Med 1987; 82: 31-4
38. Hirota Y, Kaji M, Ide S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997; 15: 962-7
39. Bridges CB, Fukuda K, Cox NJ, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2001; 50: 1-44
40. Meiklejohn G. Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982. J Infect Dis 1983; 148: 775-84
41. Sugaya N, Nerome K, Ishida M, et al. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 1994; 272: 1122-6
42. Barker WH, Mullooly JP. Influenza vaccination of elderly persons: reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980; 244: 2547-9
43. Ruben FL, Johnston F, Streiff EJ. Influenza in a partially immunized aged population: eEffectiveness of killed Hong Kong vaccine against infection with the England strain. JAMA 1974; 230: 863-6
44. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661-5
45. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-27
46. Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22: 295-302
47. Dorrell L, Hassan I, Marshall S, et al. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS 1997; 8: 776-9
48. Buxton JA, Skowronski DM, Ng H, et al. Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks. J Infect Dis 2001; 184: 188-91
49. Galbraith WM, Hobson WC, Giclas PC, et al. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 1994; 4: 201-6